Oxford Biomedica new manufacturing suite approved

Oxford Biomedica said it had received government approval for a fourth manufacturing suite within its Oxbox facility which will be used to develop a potential Covid-19 vaccine.

Approval was given by the UK Medicines & Healthcare products Regulatory Agency, the company said on Tuesday.

“Both this suite and the suite approved in September …at present will be dedicated to the manufacture of a Covid-19 viral vector vaccine candidate,” Oxford said.

“This world class facility is suitable for the manufacture of a variety of viral vectors and the approval of this fourth suite completes a phase of expansion that more than doubles Oxford Biomedica's manufacturing capacity compared to 2019, supporting further growth in revenues and partner programmes.”